Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome
Authors:
- 5 March 2013
- journal article
- case report
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 84 (12) , 1346-1348
Abstract
Objective Vascular endothelial growth factor (VEGF) plays an essential role in the pathophysiology of polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome. Anti-VEGF antibody (bevacizumab) appears to be an attractive therapeutic option. The aim of this study is to investigate the effects of bevacizumab for patients with POEMS syndrome. Methods We reported six POEMS patients treated with bevacizumab and reviewed the literature. Results The serum VEGF levels decreased immediately after bevacizumab administration in all six patients. However, four patients had entirely no clinical response, and two of them died. The remaining two showed improvement that could be explained by combined treatments. We also reviewed the literature and found 11 patients treated with bevacizumab; of these, only one was treated with bevacizumab alone. 10 had combined treatments, and four died without any response. Conclusions Both our experience and the literature suggest ambiguous effects of bevacizumab; inhibition of VEGF alone may be insufficient because multiple cytokines are upregulated, or aberrant neo-vascularization may have already fully developed in the advanced stage of POEMS syndrome.Keywords
This publication has 18 references indexed in Scilit:
- POEMS syndrome: Update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2012
- Successful treatment sequence incorporating bevacizumab for therapy of polyneuropathy in two patients with POEMS syndromeLeukemia Research, 2012
- Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndromeBone Marrow Transplantation, 2008
- Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndromeAnnals of Oncology, 2008
- Failure of Treatment with Anti-VEGF Monoclonal Antibody for Long-standing POEMS SyndromeInternal Medicine, 2007
- Bevacizumab therapy for POEMS syndromeBlood, 2006
- Bevacizumab therapy for POEMS syndromeBlood, 2005
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood, 2004
- POEMS syndrome: definitions and long-term outcomeBlood, 2003
- Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in crow-fukase (POEMS) syndromeMuscle & Nerve, 1998